Dissociation between titer of anti-ganglioside antibody and severity of symptoms in a case of Guillain-Barré syndrome with treatment-related fluctuation

Autor(es): Inoue Nami,Kunishige Makoto,Yoshida Sumiko,Oshima Yasushi,Ohnishi Yoshiaki,Kuroda Yasuhiro,Asano Atsuko,Yoshino Hiide,Matsumoto Toshio,Mitsui Takao

Resumo: Since plasma exchange (PE) and intravenous immunoglobulin (i.v.Ig) have been widely used in treatment for Guillain-Barré syndrome (GBS), early relapse and treatment-related fluctuation have been a potential problem, but little is known about the mechanism of relapse and fluctuation. We describe a patient who had GBS with treatment-related fluctuation. A 37-year-old Japanese man exhibited acute distal-dominant weakness in upper limbs after upper respiratory infection. His cranial nerve system was normal and muscle weakness was limited to upper limbs. Anti-GT1a IgG was strongly positive and anti-GQ1b IgG was also detected in his serum. Muscle weakness responded well to double-filtration plasmapheresis (DFPP) followed by i.v.Ig, but relapsed 45 days after the initial treatment. Although repeated treatments were effective, the patient showed additional minor deterioration twice. Motor nerve conduction velocities (MCVs) corresponded to the muscle weakness, but elevated level of cerebrospinal fluid (CSF) protein remained and anti-ganglioside antibody titers steadily decreased throughout the clinical course. These findings indicate that the clinical fluctuation was not due to changes in the production of anti-ganglioside antibodies but presumably to the transient beneficial effects of DFPP/i.v.Ig and the outlasting inflammatory response in peripheral nerves.

Palavras-Chave: Anti-GT1a antibody; Anti-GQ1b antibody; Acute inflammatory demyelinating polyneuropathy; Intravenous immunoglobulin; Plasma exchange; Relapse

Imprenta: Journal of the Neurological Sciences, v. 210, n. 1-2, p. 105-108, 2003

Identificador do objeto digital: 10.1016/S0022-510X(03)00031-5

Descritores: Guillain-Barre Syndrome - Biosynthesis ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Immunology

Data de publicação: 2003